S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc stock logo
CDNA
CareDx
$7.85
-4.3%
$9.72
$4.80
$12.93
$406.47M1.42904,488 shs489,991 shs
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.94
-1.5%
$21.91
$9.26
$26.70
$519.90M0.93240,082 shs138,556 shs
Invitae Co. stock logo
NVTA
Invitae
$0.00
-91.6%
$0.03
$0.02
$0.02
$214K1.5923.72 million shs183,048 shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$15.09
-3.5%
$17.96
$10.93
$30.30
$947.20M1.07939,111 shs679,991 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc stock logo
CDNA
CareDx
-3.87%-13.96%-19.13%-22.57%-7.66%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-4.14%-7.81%+2.02%-0.72%-14.84%
Invitae Co. stock logo
NVTA
Invitae
0.00%+137.50%-44.12%-98.10%-99.31%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-1.57%-7.46%-8.48%-29.26%-37.94%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CareDx, Inc stock logo
CDNA
CareDx
3.04 of 5 stars
3.31.00.04.22.10.00.6
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
1.6942 of 5 stars
3.51.00.00.02.02.50.6
Invitae Co. stock logo
NVTA
Invitae
1.8355 of 5 stars
2.50.00.04.61.41.71.3
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
1.8367 of 5 stars
3.51.00.00.03.21.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CareDx, Inc stock logo
CDNA
CareDx
2.50
Moderate Buy$11.0040.13% Upside
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.00
Buy$31.0063.67% Upside
Invitae Co. stock logo
NVTA
Invitae
1.00
Strong Sell$1.00124,900.00% Upside
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
3.00
Buy$36.60142.54% Upside

Current Analyst Ratings

Latest NVTA, CDNA, VRDN, and CSTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2024
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$29.00 ➝ $25.00
3/20/2024
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
3/1/2024
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$25.00 ➝ $28.00
3/1/2024
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$33.00 ➝ $37.00
2/29/2024
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$37.00
2/28/2024
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
2/28/2024
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$39.00 ➝ $40.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CareDx, Inc stock logo
CDNA
CareDx
$280.32M1.45N/AN/A$4.83 per share1.63
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$219.79M2.37N/AN/A$14.54 per share1.30
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$310K3,055.48N/AN/A$4.48 per share3.37

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CareDx, Inc stock logo
CDNA
CareDx
-$190.28M-$3.54N/AN/AN/A-67.88%-51.40%-37.85%5/8/2024 (Estimated)
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$57.47M-$2.16N/AN/AN/A-26.15%-14.92%-13.20%5/2/2024 (Confirmed)
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$237.73M-$5.32N/AN/AN/A-75,711.48%-121.80%-61.06%5/14/2024 (Estimated)

Latest NVTA, CDNA, VRDN, and CSTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.37N/A+$0.37N/AN/AN/A  
2/28/2024Q4 2023
CareDx, Inc stock logo
CDNA
CareDx
-$0.24-$2.21-$1.97-$2.21$63.66 million$65.57 million    
2/28/2024Q4 2023
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.84-$0.10+$0.74-$0.10$51.32 million$66.12 million
2/27/2024Q4 2023
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$0.98-$1.35-$0.37-$1.35$0.15 million$0.07 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CareDx, Inc stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CareDx, Inc stock logo
CDNA
CareDx
N/A
4.02
3.77
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/A
6.20
6.04
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.09
18.26
18.26

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CareDx, Inc stock logo
CDNA
CareDx
N/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
Invitae Co. stock logo
NVTA
Invitae
61.28%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
CareDx, Inc stock logo
CDNA
CareDx
4.20%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
7.70%
Invitae Co. stock logo
NVTA
Invitae
0.74%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
1.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CareDx, Inc stock logo
CDNA
CareDx
63551.78 million49.60 millionOptionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
61027.45 million25.34 millionOptionable
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionOptionable
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
9462.77 million61.87 millionOptionable

NVTA, CDNA, VRDN, and CSTL Headlines

SourceHeadline
Viridian Therapeutics (NASDAQ: VRDN)Viridian Therapeutics (NASDAQ: VRDN)
fool.com - April 13 at 3:28 PM
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Increase in Short InterestViridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Increase in Short Interest
americanbankingnews.com - April 13 at 3:46 AM
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Vanguard Group Inc.Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Vanguard Group Inc.
marketbeat.com - April 11 at 4:11 AM
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 7.5%Viridian Therapeutics (NASDAQ:VRDN) Trading Down 7.5%
marketbeat.com - April 10 at 2:51 PM
Buy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market PotentialBuy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potential
markets.businessinsider.com - April 6 at 2:51 AM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com - April 4 at 4:01 PM
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Buy" from BrokeragesViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Buy" from Brokerages
marketbeat.com - April 4 at 2:16 AM
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by SG Americas Securities LLCViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by SG Americas Securities LLC
marketbeat.com - April 1 at 4:23 AM
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the FirmVIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
prnewswire.com - March 29 at 9:00 AM
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)
markets.businessinsider.com - March 25 at 10:01 PM
Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 4.7% Following Analyst DowngradeViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 4.7% Following Analyst Downgrade
marketbeat.com - March 22 at 12:27 PM
B. Riley Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $25.00B. Riley Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $25.00
marketbeat.com - March 21 at 10:55 AM
Buy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED MarketBuy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Market
markets.businessinsider.com - March 20 at 8:21 PM
Unveiling 4 Analyst Insights On Viridian TherapeuticsUnveiling 4 Analyst Insights On Viridian Therapeutics
markets.businessinsider.com - March 20 at 3:20 PM
Viridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at Needham & Company LLCViridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at Needham & Company LLC
marketbeat.com - March 20 at 1:44 PM
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
investorplace.com - March 19 at 6:51 PM
VRDN Sep 2024 20.000 putVRDN Sep 2024 20.000 put
finance.yahoo.com - March 16 at 8:46 AM
VRDN Apr 2024 20.000 putVRDN Apr 2024 20.000 put
finance.yahoo.com - March 16 at 8:46 AM
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the FirmSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
stockhouse.com - March 15 at 11:23 PM
VRDN Makes Bullish Cross Above Critical Moving AverageVRDN Makes Bullish Cross Above Critical Moving Average
nasdaq.com - March 9 at 2:40 PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com - March 6 at 4:01 PM
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceViridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
finance.yahoo.com - March 5 at 10:27 AM
Buy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market PotentialBuy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market Potential
markets.businessinsider.com - March 1 at 8:01 AM
Buy Rating on Viridian Therapeutics Backed by Pipeline Progress and Phase 3 Trial PotentialBuy Rating on Viridian Therapeutics Backed by Pipeline Progress and Phase 3 Trial Potential
markets.businessinsider.com - February 29 at 3:56 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CareDx logo

CareDx

NASDAQ:CDNA
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Castle Biosciences logo

Castle Biosciences

NASDAQ:CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Invitae logo

Invitae

NYSE:NVTA
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Viridian Therapeutics logo

Viridian Therapeutics

NASDAQ:VRDN
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.